It indicated that the level of immune response of p53-wt samples was significantly higher than that of p53-mut samples in 6 cancer types (lung squamous cell carcinoma [LUSC], stomach adenocarcinoma [STAD], head and neck squamous cell carcinoma [HNSC], cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC], uterine corpus endometrial carcinoma [UCEC], and colon adenocarcinoma [COAD]), while only 2 cancer types had significantly lower levels of immune response in p53-wt samples (Figure 6B, red dots and blue dots, respectively). This evidence concerns the gene TP53 and colon adenocarcinoma.